West Pharmaceutical Services vs Ypsomed vs Insulet and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: West Pharmaceutical Services 0.872, Ypsomed 0.12, Insulet 0.802, DexCom 1.308.
* Ypsomed reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, West Pharmaceutical Services, Ypsomed, Insulet, DexCom.| Metric | West Pharmaceutical Services | Ypsomed | Insulet | DexCom |
|---|---|---|---|---|
| Market Cap | $26.44B | $5.80B | $9.23B | $32.71B |
| Revenue | $872.00M | $416.00M | $802.00M | $1.31B |
| Cost of Revenue | $543.00M | $230.00M | $239.00M | $478.00M |
| Gross Profit | $329.00M | $186.00M | $563.00M | $830.00M |
| Operating Income | $179.00M | $124.00M | $130.00M | $318.00M |
| Net Income | $154.00M | $94.00M | $95.00M | $249.00M |
| R&D Expense | $20.00M | $24.00M | $88.00M | $153.00M |
| Earnings Per Share | $2.15 | $6.9 | $1.37 | $0.64 |
| Gross Margin | 37.7% | 44.6% | 70.2% | 63.4% |
| Operating Margin | 20.5% | 29.8% | 16.2% | 24.3% |
| Net Profit Margin | 17.6% | 22.5% | 11.8% | 19.0% |
| Free Cash Flow | $81.00M | $8.00M | $59.00M | $184.00M |
| Cumulative Free Cash Flow | $3.60B | $-60.00M | $-38.00M | $3.40B |
| Operating Cash Flow | $124.00M | $199.00M | $88.00M | $269.00M |
| Cash & Equivalents | $436.00M | $32.00M | $535.00M | $1.10B |
Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.